Key Decisions in HIV Care

Download All
Hear expert perspectives on when, how, and why to consider switching ART in virologically suppressed patients, the single-tablet regimens, long-acting injectables, and more.
Daniel R. Kuritzkes, MD
person default
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
person default
Anonymous Patient
William R. Short, MD, MPH, AAHIVS

Switch Strategies

Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 10, 2021

In this concise presentation, Dr. Daniel Kuritzkes discusses recent data on new long-acting injectable ART.

Daniel R. Kuritzkes, MD Released: May 19, 2021

See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Daniel R. Kuritzkes, MD Released: June 4, 2021

Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Daniel R. Kuritzkes, MD Released: July 7, 2021

In this case example, learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: October 4, 2021

Learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: October 4, 2021

Learn why one patient feels that long-acting ART gave her a lot of her life back.

person default Anonymous Patient Released: September 16, 2021

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: October 13, 2021

In this case example, learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted.

William R. Short, MD, MPH, AAHIVS Released: September 28, 2021

Learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted

William R. Short, MD, MPH, AAHIVS Released: September 30, 2021

Listen as William R. Short, MD, MPH, AAHIVS, discusses the data to help you determine when switching to 2-drug single-tablet regimens may be warranted.

William R. Short, MD, MPH, AAHIVS Released: November 10, 2021

I was hesitant to switch, but I asked my doctor a million and one questions because I think that taking an active role in your own health and being informed helps ensure you are getting the best care possible.

person default Anonymous Patient Released: September 27, 2021

In this case example, learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: November 24, 2021

Learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: December 1, 2021
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue